Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
Study Results
Related Studies
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS (CURRENT/OASIS7)
This study has been completed.
Study NCT00335452 Information provided by Sanofi
First Received on June 8, 2006. Last Updated on November 9, 2010
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Acute Coronary Disease
Angina Unstable
Additional conditions recognized in this trial
Angina Pectoris
Angina, Unstable
Coronary Artery Disease
Coronary Disease
Myocardial Infarction
More general conditions related to this trial
Arterial Occlusive Diseases
Arteriosclerosis
Cardiovascular Diseases
Chest Pain
Heart Diseases
Myocardial Ischemia
Pain
Signs and Symptoms
Vascular Diseases
Interventions listed in this trial
Clopidogrel
acetylsalicyclic acid (ASA)
Additional drug interventions recognized in this trial
Aspirin
Platelet Aggregation Inhibitors
Ticlopidine
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antipyretics
Antirheumatic Agents
Cardiovascular Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Purinergic Agents
Purinergic Antagonists
Purinergic P2 Receptor Antagonists
Purinergic P2Y Receptor Antagonists
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Sanofi
Bristol-Myers Squibb
Back to top of Main Content
